Cedars-Sinai Appoints Robert A. Figlin, MD, to Lead New Initiative to Integrate Cancer Care Across Health System


Get Permission

Robert A. Figlin, MD

Robert A. Figlin, MD

Cedars-Sinai recently announced it has appointed Robert A. Figlin, MD, to integrate research and clinical strategies across the organization in an effort to standardize cancer care and ensure optimal treatment of patients. Dr. Figlin will serve as Deputy Director of the Integrated Oncology Service Line at the Samuel Oschin Comprehensive Cancer Institute. Previously, he was Director of the Hematology Oncology Division.

Dr. Figlin is an experienced leader who knows cancer care in the Cedars-Sinai system, throughout Los Angeles and beyond.
— Steven Piantadosi, MD, PhD

In his new role, Dr. Figlin will work with clinicians and investigators to unify the health system’s approach to treating cancer. Patients will receive the same level of quality care whether they are treated at Cedars-Sinai’s main campus or one of its affiliates, including Tower Hematology Oncology in Beverly Hills and The Angeles Clinic in Los Angeles. Dr. Figlin will continue working to develop clinical trials, translate research findings from the laboratory to the clinical setting, and lead initiatives such as Cedars-Sinai’s effort to contain the high cost of cancer drugs.

An Experienced Leader

“Dr. Figlin is an experienced leader who knows cancer care in the Cedars-Sinai system, throughout Los Angeles and beyond,” said Steven Piantadosi, MD, PhD, Director of the Samuel ­Oschin Comprehensive Cancer Institute and Professor of Medicine at Cedars-Sinai.

Dr. Figlin joined Cedars-Sinai 6 years ago and is the Steven Spielberg Family Chair in Hematology Oncology. Over the years, he has established the Experimental Therapeutics Program and successfully recruited clinical and research faculty in critical specialty areas such as breast cancer, bone marrow transplant, gastrointestinal oncology, genitourinary oncology, survivorship, and cancer biology.

Dr. Figlin said that this new position will provide additional opportunities to enhance the lives of cancer patients while advancing significant research goals. ■


Advertisement

Advertisement



Advertisement